{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"80.5","value":"66.9"}]}],"title":"CD3/4 at Day +28"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"137.4","value":"109.9"}]}],"title":"CD3/8 at Day +28"}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"}],"units":"Participants"}],"description":"CD4 and CD8 values at Day +28. Reported as mean (standard deviation).","dispersionType":"Standard Deviation","groups":[{"description":"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -15 to -12, busulfan IV on days -14 to -13, DLI on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI on day -10.\n\nTRANSPLANT: Patients undergo allogeneic PBSCT on day 0.\n\nGVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28\n\nFludarabine phosphate: Given IV\n\nBusulfan: Given IV\n\nTotal-Body Irradiation: Undergo TBI\n\nTherapeutic Allogeneic Lymphocytes: Undergo DLI\n\nCyclophosphamide: Given IV\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT\n\nPeripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSCT\n\nTacrolimus: Given IV\n\nMycophenolate Mofetil: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Treatment (RIC and allogeneic PBSCT)"}],"paramType":"MEAN","populationDescription":"Participants surviving to Day +28 with evaluable data. This excludes the one subject who was a graft failure and anyone who died before 28 days.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Immune Reconstitution at Day +28","type":"SECONDARY","unitOfMeasure":"cells/mm³"}